# Marathon Asset Management

> Marathon Asset Management is a VC fund backing Biotechnology. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 17
- Last investment: Jul 2026
- Lead investor: 65%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/marathon-asset-management
- Website: http://www.marathonfund.com

Marathon Asset Management is a VC fund in New York focused on Biotechnology and Pharmaceutical. Marathon Asset Management LP is a global alternative investment and asset management company with approximately $11 billion in capital under management. Marathon's core businesses include hedge funds, structured finance, emerging markets, and real estate. Founded in 1998, the firm has 130 professionals worldwide with headquarters in New YorkCity and investment offices in London and Singapore.

## Contacts

5 contacts available for Marathon Asset Management. Shizune tracks 3 team members at Marathon Asset Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/marathon-asset-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 29% |
| Pharmaceutical | 4 | 24% |
| Medical | 3 | 18% |
| Health Care | 3 | 18% |
| Therapeutics | 3 | 18% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Debt Financing | 6 | 35% |
| Post-IPO Debt | 5 | 29% |
| Private Equity | 2 | 12% |
| Funding Round | 1 | 6% |
| Post-IPO Equity | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 76% |
| Canada | 1 | 6% |
| France | 1 | 6% |
| United Kingdom | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bruce Richards | Chairman and Chief Executive Officer | 1 | — |
| Evan Bedil | Managing Director, Head Healthcare Credit and Drug Royalty Monetization Strategy | 0 | — |
| Randy Raisman | Managing Director | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jack Doheny Company | Jack Doheny Company provides sewer cleaning and electric utility solutions for municipalities, gas and oil, and environmental sectors. | $175M | Debt Financing | Jul 08, 2026 |  |
| Lone Star Funds | Lone Star invests globally in distressed assets. Since the establishment of its first fund in 1995, Lone Star has organized twelve private equity funds with aggregate capital commitments totaling over $45 billion. | $235M | Debt Financing | Feb 18, 2026 |  |
| Rovia Clinical Research | Rovia Clinical Research is a US-based multi-specialty clinical research site network that partners with healthcare providers, pharmaceutical and biotech companies, and contract research organizations. |  | Debt Financing | Nov 06, 2025 |  |
| NN | NN, Inc. is a leading global manufacturer of metal bearing, plastic, rubber, and precision metal components. The company was founded in 1980 and is headquartered in Johnson City, Tenn. With over 4,300 employees at our 26 manufacturing facilities in North America, South America, Eastern Europe, Western Europe, and Asia, we proudly serve customersaround the globe with high quality precision solutions. | $118M | Post-IPO Debt | Apr 16, 2025 |  |
| Stockdale Capital Partners | Stockdale Capital Partners is a growing Los Angeles based vertically-integrated real estate investment firm, affiliated with Stockdale Management, a property management firm. We’re championing innovation, sustainability and design that brings people together, enhances quality of life and builds community. Focused on opportunistic investments acrossthe Southwest, we have four offices and 75 employees in four states. | $164M | Debt Financing | Jan 09, 2025 |  |
| Sunbelt Modular | Sunbelt Modular is a wholesale manufacturing firm that constructs commercial modular buildings for various industries. |  | Debt Financing | Nov 22, 2024 |  |
| GEMS Education | GEMS Education is an education company that advances all through their schools, consulting practices, and charitable foundations. Through its Varkey Foundation it campaigns for, and support initiatives that change lives through education. GEMS Education is located in the U.A.E. and it was founded in 1959. |  | Venture - Series Unknown | Jun 18, 2024 |  |
| Theratechnologies | Theratechnologies Inc., a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that increases the target protein's resistance to enzymatic degradation. Its lead product is tesamorelin, whichcompleted its phase III clinical trial for the treatment of HIV-associated lipodystrophy and is in phase II clinical trials for the treatment of mild cognitive impairment and growth hormone deficient abdominal obesity. The company also develops Acute kidney injury, a preclinical stage product. It has a license agreement with PDC Biotech GmbH to use the antagonists of the prostaglandin F2a receptor in pre-term labor and primary dysmenorrheal; and OctoPlus N.V. to develop and commercialize GLP-1 portfolio of analogues. The company also has a collaboration and licensing agreement with EMD Serono, Inc. for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded in 1993 and is headquartered in Montreal, Canada. | $60M | Post-IPO Debt | Jul 27, 2022 |  |
| Acer Therapeutics | Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious rare, and life-threatening diseases with critical unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (ataste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts. | $48.5M | Post-IPO Debt | Mar 07, 2022 |  |
| BigBear.ai | BigBear.ai is a decision dominance company serving the national defense and intelligence communities. The Company delivers high-end capabilities across the data and digital spectrum to deliver information superiority and decision support. BigBear.ai provides a comprehensive suite of solutions including artificial intelligence and machine learning,data science, advanced analytics, offensive and defensive cyber, data management, cloud solutions, digital engineering, and systems integration. | $200M | Post-IPO Debt | Dec 08, 2021 |  |

10 of 17 investments shown.

## Co-investors
- Arbour Lane — VC Fund, 2 deals together
- [Brookfield Asset Management](https://shizune.co/investors/profile/brookfield-asset-management) — VC Fund, 2 deals together
- [MidOcean Partners](https://shizune.co/investors/profile/midocean-partners) — VC Fund, 2 deals together
- [Vulcan Capital](https://shizune.co/investors/profile/vulcan-capital) — VC Fund, 2 deals together
- [Anchorage Capital Partners](https://shizune.co/investors/profile/anchorage-capital-partners) — VC Fund, 1 deal together
- [Attestor Capital LLP](https://shizune.co/investors/profile/attestor-capital-llp) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund
- [The FSE Group](https://shizune.co/investors/profile/finance-south-east) — VC Fund

## FAQ

### What does Marathon Asset Management invest in?

Marathon Asset Management invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Marathon Asset Management?

Public channels for Marathon Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Marathon Asset Management?

The team at Marathon Asset Management includes Bruce Richards (Chairman and Chief Executive Officer), Evan Bedil (Managing Director, Head Healthcare Credit and Drug Royalty Monetization Strategy) and Randy Raisman (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co